Corvus Pharmaceuticals
CRVS • NASDAQ
Corvus Pharmaceuticals is a biotechnology company in the healthcare sector trading on NASDAQ, led by CEO Richard A. Miller, with a market cap of $1.2B.
CEORichard A. Miller
Next Earnings
Upcoming earnings announcement for Corvus Pharmaceuticals
Date
Thursday, May 7, 2026 (in a month)
Timing
After Market Close (4:00 PM New York)
Fiscal Period
Q1 2026
EPS Estimate
-$0.15
Revenue Estimate
$620.0K
Earnings History
Past 12 earnings reports for Corvus Pharmaceuticals
| Date | Period | EPS | EPS Surprise | Revenue | Rev. Surprise | Filing |
|---|---|---|---|---|---|---|
| Mar 12, 2026 | Q4 2025 | -$0.15Est: -$0.14 | -7.1% | -Est: $620.0K | -100.0% |  10-K |
| Nov 4, 2025 | Q3 2025 | -$0.12Est: -$0.14 | +14.3% | - | — | 10-Q |
| Aug 7, 2025 | Q2 2025 | -$0.10Est: -$0.13 | +23.1% | - | — | 10-Q |
| May 8, 2025 | Q1 2025 | -$0.13Est: -$0.12 | -8.3% | - | — | 10-Q |
| Mar 25, 2025 | Q4 2024 | -$0.18Est: -$0.12 | -50.0% | - | — | 10-K |
| Nov 12, 2024 | Q3 2024 | -$0.60Est: -$0.11 | -445.5% | - | — | 10-Q |
| Aug 6, 2024 | Q2 2024 | -$0.07Est: -$0.12 | +41.7% | - | — | 10-Q |
| May 6, 2024 | Q1 2024 | -$0.12Est: -$0.11 | -9.1% | - | — | 10-Q |
| Mar 19, 2024 | Q4 2023 | -$0.14Est: -$0.12 | -16.7% | - | — | 10-K |
| Nov 7, 2023 | Q3 2023 | -$0.12Est: -$0.12 | 0.0% | - | — | — |
| Aug 8, 2023 | Q2 2023 | -$0.14Est: -$0.14 | 0.0% | - | — | 10-Q |
| May 8, 2023 | Q1 2023 | -$0.17Est: -$0.16 | -6.3% | - | — | — |